ProFound™ Therapeutics
ProFound Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel protein drugs and drug targets. The company’s ProFoundry™ Platform uses state-of-the-art protein detection technologies, computational methods and high-throughput experimental assays to systematically identify novel proteins and define their connectivity, functionality, and roles in health and disease. The result is the identification of a broad new class of therapeutic targets that is leading to a portfolio of fist-in-class medicines.
Latest News from ProFound™ Therapeutics
- Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK 11.20.2025
- Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer 06.12.2024
- Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics 10.02.2023
- Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins with the Potential to Enable a Multitude of New Medicines 05.26.2022